{
    "nctId": "NCT06252662",
    "briefTitle": "Liposomal Bupivacaine vs Bupivacaine With Dexmedetomidine in Erector Spinae Plane Blocks for Mastectomies",
    "officialTitle": "Liposomal Bupivacaine vs Bupivacaine With Dexmedetomidine in an Erector Spinae Plane Block for Mastectomies in Cancer Patients: A Randomized Control Trial",
    "overallStatus": "NOT_YET_RECRUITING",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE4",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 200,
    "primaryOutcomeMeasure": "Is bupivacaine with dexmedetomidine superior to liposomal bupivacaine in both density and duration?",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients requiring any variation of mastectomy with or without axillary lymph node dissection.\n* Patient agrees to a peripheral nerve block.\n* Patient agrees to be a study participant.\n* APS team believes a peripheral nerve block would be appropriate for the patient after reviewing medical/surgical history.\n* Surgeon agrees with the block plan by APS.\n\nExclusion Criteria:\n\n* Patient declines a peripheral nerve block.\n* Patient declines to be a study participant.\n* APS team believes a peripheral nerve block is not clinically indicated.\n* Surgeon does not want a peripheral nerve block.\n* Patient has allergy to local anesthestic.\n* Patient has an active infection at the site of the peripheral nerve block.\n* Patient with pre-existing neural deficits along the distribution of the block.\n* Patient with coagulopathy.\n* Patient taking antithrombotic drugs outside the ASRA guidelines.\n* Patients weight is less that 50 kg due to concerns for local anesthetic toxicity syndrome.",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}